ER-mediated anti-tumor effects of shikonin on breast cancer

Yang Yang1, Wenya Gao1, Shiying Tao1

  • 1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.

Insights

Shikonin (SK) exhibits anti-tumor effects by inhibiting breast cancer (BC) cell proliferation and inducing apoptosis. These effects are linked to the downregulation of estrogen receptor alpha (ERα) and G protein-coupled estrogen receptor (GPER) signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Estrogen receptor (ER) is prevalent in breast cancer (BC).
  • G protein-coupled estrogen receptor (GPER) influences BC tumor development.
  • Shikonin (SK) is a natural compound with known anti-tumor properties.

Purpose of the Study:

  • To investigate shikonin's effects on BC cell proliferation, cell cycle, and apoptosis.
  • To determine if these effects involve the ER/GPER signaling pathway.

Main Methods:

  • Assessed shikonin's impact on MCF-7 and SK-BR-3 BC cell lines.
  • Analyzed cell proliferation, cell cycle arrest (G0/G1), and apoptosis.
  • Examined the expression levels of ERα, GPER, EGFR, and p-ERK.
  • Utilized GPER antagonist G15 to evaluate pathway involvement.

Main Results:

  • Shikonin inhibited MCF-7 cell proliferation via G0/G1 arrest and apoptosis.
  • Shikonin induced apoptosis in SK-BR-3 cells, reducing proliferation.
  • Shikonin downregulated ERα and GPER expression in both cell lines, independent of estrogen levels.
  • Shikonin suppressed EGFR and p-ERK expression, which was further confirmed by GPER antagonist treatment.

Conclusions:

  • Shikonin demonstrates anti-tumor activity against MCF-7 and SK-BR-3 breast cancer cells.
  • The anti-cancer effects are associated with the inhibition of ERα and GPER.
  • Downregulation of the EGFR/p-ERK pathway mediated by ERα and GPER inhibition contributes to shikonin's efficacy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K